Crosslinking efficacy supported by Siena Study

The results of the Siena Eye Cross Study showed a long-term stability of keratoconus after crosslinking without relevant side effects, said Cosimo Mazzotta, M.D., Santa Maria delle Scotte Hospital, Siena University, Italy in the February issue of the American Journal of Ophthalmology.
In the perspective, nonrandomized, open trial, the researchers treated 363 eyes with progressive keratoconus with riboflavin ultraviolet A collagen cross-linking. After a minimum 48 months post-op (mean, 52.4 months; range, 48 to 60 months), the eyes were evaluated for uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), spherical spectacle-corrected visual acuity, endothelial cells count, optical and ultrasound pachymetry, corneal topography and surface aberrometry, tomography, posterior segment optical coherence tomography, and in vivo confocal microscopy.
Dr. Mazzotta said keratoconus stability was detected in all 44 eyes after 48 months of minimum follow-up; fellow eyes showed a mean progression of 1.5 D in more than 65% after 24 months; then they were treated. The mean K value was reduced by a mean of 2 D, and coma aberration reduction with corneal symmetry improvement was observed in more than 85%. The mean BSCVA improved by 1.9 Snellen lines, and the UCVA improved by 2.7 Snellen lines.
The UCVA and BSCVA improvements were supported by clinical, topographic, and wavefront modifications induced by the treatment.

Source: http://www.ajo.com/article/PIIS0002939409008083/abstract?rss=yes
Reported by: EyeWorld News Services